News Releases

Date Title and Summary View
Apr 20, 2021
Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review
EMA Confirms Overall Benefit-Risk Profile Remains Positive Company to update the COVID-19 Vaccine Janssen Summary of Product Characteristics and Package Leaflet to include important information on very rare adverse event Johnson & Johnson remains committed to supplying 200 million doses of its
Apr 20, 2021
Johnson & Johnson Announces Dividend Increase of 5.0%
NEW BRUNSWICK, N.J. , April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend, from $1.01 per share to $1.06 per share. "Despite a year of unprecedented disruption, Johnson & Johnson
Apr 20, 2021
Johnson & Johnson Reports 2021 First-Quarter Results:
- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%* - 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%* - Company increased 2021 Full-Year guidance for adjusted
Apr 19, 2021
Apr 19, 2021
Apr 16, 2021
Apr 12, 2021
Mar 29, 2021
Mar 26, 2021
Mar 19, 2021
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.